Logo image of KZIA

KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock Fundamental Analysis

USA - NASDAQ:KZIA - US48669G3039 - ADR

7.14 USD
+0.36 (+5.31%)
Last: 10/7/2025, 4:29:57 PM
7.12 USD
-0.02 (-0.28%)
After Hours: 10/7/2025, 4:29:57 PM
Fundamental Rating

1

Taking everything into account, KZIA scores 1 out of 10 in our fundamental rating. KZIA was compared to 536 industry peers in the Biotechnology industry. KZIA has a bad profitability rating. Also its financial health evaluation is rather negative. KZIA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KZIA had negative earnings in the past year.
KZIA had a negative operating cash flow in the past year.
In the past 5 years KZIA always reported negative net income.
In the past 5 years KZIA always reported negative operating cash flow.
KZIA Yearly Net Income VS EBIT VS OCF VS FCFKZIA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -158.60%, KZIA is not doing good in the industry: 86.94% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -158.6%
ROE N/A
ROIC N/A
ROA(3y)-88.87%
ROA(5y)-67.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KZIA Yearly ROA, ROE, ROICKZIA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KZIA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KZIA Yearly Profit, Operating, Gross MarginsKZIA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K -1M

More info and screens

0

2. Health

2.1 Basic Checks

KZIA has more shares outstanding than it did 1 year ago.
KZIA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for KZIA is higher compared to a year ago.
KZIA Yearly Shares OutstandingKZIA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
KZIA Yearly Total Debt VS Total AssetsKZIA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -14.14, we must say that KZIA is in the distress zone and has some risk of bankruptcy.
KZIA's Altman-Z score of -14.14 is on the low side compared to the rest of the industry. KZIA is outperformed by 79.48% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.14
ROIC/WACCN/A
WACCN/A
KZIA Yearly LT Debt VS Equity VS FCFKZIA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

KZIA has a Current Ratio of 0.21. This is a bad value and indicates that KZIA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of KZIA (0.21) is worse than 95.52% of its industry peers.
A Quick Ratio of 0.21 indicates that KZIA may have some problems paying its short term obligations.
The Quick ratio of KZIA (0.21) is worse than 95.15% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
KZIA Yearly Current Assets VS Current LiabilitesKZIA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 80.50% over the past year.
Looking at the last year, KZIA shows a very strong growth in Revenue. The Revenue has grown by 8004.84%.
Measured over the past years, KZIA shows a very strong growth in Revenue. The Revenue has been growing by 87.69% on average per year.
EPS 1Y (TTM)80.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.63%
Revenue 1Y (TTM)8004.84%
Revenue growth 3Y-46.59%
Revenue growth 5Y87.69%
Sales Q2Q%-100%

3.2 Future

KZIA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -75.24% yearly.
The Revenue is expected to grow by 7.54% on average over the next years.
EPS Next Y-236463.64%
EPS Next 2Y-3300.8%
EPS Next 3Y-864.58%
EPS Next 5Y-75.24%
Revenue Next Year-99.85%
Revenue Next 2Y-95.24%
Revenue Next 3Y-88.86%
Revenue Next 5Y7.54%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
KZIA Yearly Revenue VS EstimatesKZIA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
KZIA Yearly EPS VS EstimatesKZIA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KZIA. In the last year negative earnings were reported.
Also next year KZIA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KZIA Price Earnings VS Forward Price EarningsKZIA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KZIA Per share dataKZIA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A cheap valuation may be justified as KZIA's earnings are expected to decrease with -864.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3300.8%
EPS Next 3Y-864.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KZIA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KAZIA THERAPEUTICS-SPON ADR

NASDAQ:KZIA (10/7/2025, 4:29:57 PM)

After market: 7.12 -0.02 (-0.28%)

7.14

+0.36 (+5.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-10 2025-06-10/amc
Earnings (Next)N/A N/A
Inst Owners10.68%
Inst Owner Change-0.18%
Ins Owners8.48%
Ins Owner ChangeN/A
Market Cap39.91M
Analysts82.5
Price Target14.28 (100%)
Short Float %4.74%
Short Ratio0.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-74.66%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.82
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-16.9
EYN/A
EPS(NY)-8.55
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0.28
BVpS-0.45
TBVpS-2.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -158.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.87%
ROA(5y)-67.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -14.14
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.63%
EPS Next Y-236463.64%
EPS Next 2Y-3300.8%
EPS Next 3Y-864.58%
EPS Next 5Y-75.24%
Revenue 1Y (TTM)8004.84%
Revenue growth 3Y-46.59%
Revenue growth 5Y87.69%
Sales Q2Q%-100%
Revenue Next Year-99.85%
Revenue Next 2Y-95.24%
Revenue Next 3Y-88.86%
Revenue Next 5Y7.54%
EBIT growth 1Y-55.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.18%
OCF growth 3YN/A
OCF growth 5YN/A